Oxytocin or Galantamine Versus Placebo for the Treatment of Negative Symptoms and Cognitive Impairments in Schizophrenia
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- William T Carpenter, M.D.
Maryland Psychiatric Research Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Baltimore Va Medical Center
Baltimore, Maryland, United States
- Community Mental Health Centers
Baltimore, Maryland, United States
- Keypoint Community Mental Health Centers
Baltimore, Maryland, United States
- Maryland Psychiatric Research Center
Baltimore, Maryland, United States
- Maryland Psychiatric Research Center
Catonsville, Maryland, United States
- Keypoint Mental Health Center
Dundalk, Maryland, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Feb 2010
- Primary completion
- 31 Jul 2014
- Completion
- 31 Jul 2014
- Last update posted
- 12 Jan 2022
- Registered enrollment
- 86
- Registry id
- NCT01012167
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.